PREMED-F1: FEASIBILITY OF A RANDOMIZED CONTROLLED TRIAL TO COMPARE THE USE OF CETIRIZINE AS A REPLACEMENT FOR DYPHENHYDRAMINE TO PREVENT REACTIONS LINKED TO PACLITAXEL PERFUSION

Registry ID

2020-2110

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

CENTRE INTEGRE UNIVERSITAIRE DE SANTE ET DE SERVICES SOCIAUX DE L'EST DE MONTREA

Start date

2020-02-05

Last update

2019-12-27

Conditions

• ALLERGIES

Related clinical trials

• AN OPEN-LABEL, MULTI-CENTER PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PREVIOUS NOVARTIS SPONSORED REMIBRUTINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED TREATMENT WITH REMIBRUTINIB
• A PHASE 1B, OPEN-LABEL, EXPLORATORY STUDY EVALUATING THE EFFECTS OF INHALED EPINEPHRINE IN INDIVIDUALS EXPERIENCING SYSTEMIC ALLERGIC REACTIONS DURING ALLERGY TESTING, IMMUNOTHERAPY OR ORAL CHALLENGES

View on source registry